These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28429280)

  • 21. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
    Shu Q; Antalffy B; Su JM; Adesina A; Ou CN; Pietsch T; Blaney SM; Lau CC; Li XN
    Clin Cancer Res; 2006 Aug; 12(15):4687-94. PubMed ID: 16899619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
    Gupta R; Bhatt LK; Momin M
    Toxicol Appl Pharmacol; 2019 Aug; 377():114631. PubMed ID: 31228495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells.
    Ceccarelli V; Ronchetti S; Marchetti MC; Calvitti M; Riccardi C; Grignani F; Vecchini A
    Biochim Biophys Acta Gene Regul Mech; 2020 Feb; 1863(2):194481. PubMed ID: 31923609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.
    Yuan Z; Chen S; Gao C; Dai Q; Zhang C; Sun Q; Lin JS; Guo C; Chen Y; Jiang Y
    Bioorg Chem; 2019 Jun; 87():200-208. PubMed ID: 30901675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise A; Momparler RL
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calbindin-D28k in subsets of medulloblastomas and in the human medulloblastoma cell line D283 Med.
    Katsetos CD; Herman MM; Krishna L; Vender JR; Vinores SA; Agamanolis DP; Schiffer D; Burger PC; Urich H
    Arch Pathol Lab Med; 1995 Aug; 119(8):734-43. PubMed ID: 7646332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts.
    Schmoch T; Gal Z; Mock A; Mossemann J; Lahrmann B; Grabe N; Schmezer P; Lasitschka F; Beckhove P; Unterberg A; Herold-Mende C
    Anticancer Res; 2016 Apr; 36(4):1489-96. PubMed ID: 27069124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells.
    Li XN; Parikh S; Shu Q; Jung HL; Chow CW; Perlaky L; Leung HC; Su J; Blaney S; Lau CC
    Clin Cancer Res; 2004 Feb; 10(3):1150-9. PubMed ID: 14871995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.
    Alshawli AS; Wurdak H; Wood IC; Ladbury JE
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1429. PubMed ID: 32720471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.
    Xu J; Zhou JY; Tainsky MA; Wu GS
    Cancer Res; 2007 Feb; 67(3):1203-11. PubMed ID: 17283156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
    Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
    Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.
    Jung Y; Park J; Kim TY; Park JH; Jong HS; Im SA; Robertson KD; Bang YJ; Kim TY
    J Mol Med (Berl); 2007 Oct; 85(10):1137-48. PubMed ID: 17571247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.